Considering that PD-1/L1 are some of the most lucrative drug treatments across the industry, this could be a major coup for any mRNA developer that manages to successfully co-develop such a treatment.

They could also offer a more potent option to conventional flu shots, according to mRNA vaccine developers. Current flu vaccines generally offer only around 40% to 60% protective efficacy ...

Messenger RNA (mRNA) is the genetic blueprint that tells cells how to produce proteins. It plays a vital role in mRNA vaccines, such as those used for COVID-19, and is also a promising tool for ...

Kennedy Jr. has alluded to in the past, this could have major repercussions for vaccine developers. Companies like Moderna (NASDAQ:MRNA) spend years playing by the rules of the FDA. If authorities ...

With the help of mRNA technology proven effective during the COVID pandemic, researchers are now closer than ever to creating viable cancer vaccines. In an interview with Wired, Lennard Lee ...

Federal support for mRNA vaccine research appears in jeopardy after KFF Health News reported Sunday that officials at the National Institutes of Health have directed scientists to remove all ...

Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...

Get Instant Summarized Text (Gist) The NIH has reportedly advised scientists to omit mRNA vaccine references from grant applications, suggesting a potential shift away from this research area ...

Scientists at Shinshu University School of Medicine have developed a synthetic mRNA that, when injected, revitalizes the immune system to recognize and attack metastasizing cancer cells.